Stay updated on Nivolumab ± Ipilimumab in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab ± Ipilimumab in Ovarian Cancer Clinical Trial page.

Latest updates to the Nivolumab ± Ipilimumab in Ovarian Cancer Clinical Trial page
- Check2 days agoChange DetectedThe page revision was updated to v3.5.4 from v3.5.3, signaling a maintenance update to the page content. This change represents an administrative refresh rather than a substantive alteration to the study record.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoChange Detected- The page now shows Revision: v3.5.3, replacing the earlier Revision: v3.5.2. This is a minor page/document revision update and does not modify study data or functionality.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedRevision tag updated from v3.5.0 to v3.5.2 on the page.SummaryDifference0.0%

- Check52 days agoChange DetectedRevision notes updated: added 'Revision: v3.5.0' and removed 'Revision: v3.4.3'.SummaryDifference0.0%

- Check66 days agoChange DetectedRevision tag updated to v3.4.3 (replacing the previous v3.4.2).SummaryDifference0.0%

- Check95 days agoChange DetectedAdded Primary peritoneal carcinoma to the study conditions and a Resources link for the Genetic and Rare Diseases Information Center. Updated page revision to v3.4.2 and removed the government funding lapse notice along with the previous revision note v3.4.1.SummaryDifference0.2%

Stay in the know with updates to Nivolumab ± Ipilimumab in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab ± Ipilimumab in Ovarian Cancer Clinical Trial page.